Talphera, Inc. (TLPH) Stock

Healthcare · Drug Manufacturers - Specialty & Generic · Member of Other US Stocks

Talphera, Inc. (TLPH) closed at USD 1.06 on 2026-10-14, a change of -18.5 % over the past year, with a market capitalization of USD 55.54M.

Talphera, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Talphera, Inc. key figures

Previous close

USD 1.06 (2026-10-14)

1-year change

-18.5 %

Market cap

USD 55.54M

Enterprise value

USD 44.96M

P/E ratio (trailing)

-4.12

P/E ratio (forward)

-4.79

EPS (trailing)

-0.26

EPS (forward)

-0.22

PEG ratio

n/a

Price to book

3.85

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.57

Employees

12

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Talphera, Inc.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Talphera, Inc. and compare it with other stocks.